India Set to Revolutionize Weight-Loss Drug Market with Patent Expiry

India is poised to significantly reduce the cost of weight-loss drugs following the upcoming expiration of Novo Nordisk's patent on semaglutide in March. This development could lead to a price drop of up to 90%, making these medications more accessible in a country grappling with obesity and diabetes. Analysts forecast that the semaglutide market in India could reach $1 billion, with multiple Indian pharmaceutical companies already preparing to produce generic versions. As the world's diabetes capital, India's shift to affordable weight-loss solutions could transform health outcomes for millions. However, concerns about potential misuse of these drugs remain prevalent.

Key Details: • Patent for semaglutide expires in March 2024. • Generic versions expected to reduce costs to around $77 per month initially, potentially dropping to $40. • At least 10 Indian companies, including Dr. Reddy’s and Cipla, are gearing up for production. • Eli Lilly's Mounjaro has quickly become a top pharmaceutical brand in India since its launch. • Potential side effects include nausea, diarrhea, and abdominal pain.